Upregulation of desmoglein 2 and its clinical value in lung adenocarcinoma: a comprehensive analysis by multiple bioinformatics methods

Ruiying Sun¹, Chao Ma¹, Wei Wang¹ and Shuanying Yang¹

¹Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China
²Department of Anesthesiology, Xi’an Children Hospital, Xi’an, Shaanxi, China

ABSTRACT

Background. Desmoglein-2 (DSG2), a desmosomal adhesion molecule, is found to be closely related to tumorigenesis in recent years. However, the clinical value of DSG2 in lung adenocarcinoma remains unclear.

Methods. Real-time reverse transcription-quantitative polymerase chain reaction (qRT-PCR) was utilized to detect the expression of DSG2 in 40 paired lung adenocarcinoma tissues and corresponding non-cancerous tissues. Data from The Cancer Genome Atlas (TCGA) and Oncomine datasets were also downloaded and analyzed. The correlation between DSG2 and clinicopathological features was investigated. The expression of DSG2 protein by immunohistochemical was also detected from tissue microarray and the Human Protein Atlas database. Integrated meta-analysis combining the three sources (qRT-PCR data, TCGA data and Oncomine datasets) was performed to evaluate the clinical value of DSG2. Univariate and multivariate Cox regression analyses were used to explore the prognostic value of DSG2. Then, co-expressed genes were calculated by Pearson correlation analysis. Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were used to investigate the underlying molecular mechanism. The expression level in lung adenocarcinoma and prognostic significance of the top ten co-expressed genes were searched from Gene Expression Profiling Interactive Analysis (GEPIA) online database.

Results. DSG2 was highly expressed in lung adenocarcinoma tissues based on qRT-PCR, TCGA and Oncomine datasets. The protein expression of DSG2 was also higher in lung adenocarcinoma. According to qRT-PCR and TCGA, high DSG2 expression was positively associated with tumor size ($p = 0.027$, $p = 0.001$), lymph node metastasis ($p = 0.014$, $p < 0.001$) and TNM stage ($p = 0.023$, $p < 0.001$). The combined standard mean difference values of DSG2 expression based on the three sources were 1.30 (95% confidence interval (CI): 1.08–1.52) using random effect model. The sensitivity and specificity were 0.73 (95% CI [0.69–0.76]) and 0.96 (95% CI [0.89–0.98]). The area under the curve based on summarized receiver operating characteristic (SROC) curve was 0.79 (95% CI [0.75–0.82]). Survival analysis revealed that high DSG2 expression was associated with a short overall survival (hazard ratio [HR] = 1.638; 95% CI [1.214–2.209], $p = 0.001$) and poor progression-free survival (HR = 1.475; 95% CI [1.102–1.974], $p < 0.001$). A total of 215 co-expressed genes were identified. According to GO and KEGG analyses, these co-expressed genes may be involved in “cell division”,
“cytosol”, “ATP binding” and “cell cycle”. Based on GEPIA database, seven of the top ten co-expressed genes were highly expressed in lung adenocarcinoma (DSC2, SLC2A1, ARNTL2, ERO1L, ECT2, ANLN and LAMC2). High expression of these genes had shorter overall survival.

Conclusions. The expression of DSG2 is related to the tumor size, lymph node metastasis and TNM stage. Also, DSG2 predicts poor prognosis in lung adenocarcinoma.

Subjects Bioinformatics, Oncology, Respiratory Medicine
Keywords DSG2, Lung adenocarcinoma, Prognosis, TCGA

INTRODUCTION

Lung cancer is considered to be the leading cause of cancer death in both men and women worldwide. Lung adenocarcinoma (LUAD), accounts for approximately 40% of all lung cancers, is the most common subtype and leads to more than 500,000 deaths each year (Ferlay et al., 2010). For all stages combined, the survival of lung cancer is about 18%. However, most lung cancer is typically diagnosed at a distant stage which causes the 5-year survival rates is 5% (Siegel, Miller & Jemal, 2018). Thus, it is important to identify the potential diagnostic and prognostic markers for patients with LUAD.

Desmosomal cadherins family is one major subfamily of cadherins which comprised two different cadherins—desmogleins and desmocollins (Lowndes et al., 2014). Desmogleins consist of DSG1, DSG2, DSG3 and DSG4. DSG2 is expressed in all desmosome-bearing tissues and some epithelial tissues, such as cardiac muscle, skin and intestinal epithelium (Schafer, Stumpp & Franke, 1996; Ungewiss et al., 2018). As a member of cadherins, DSG2 is an important regulator of growth and survival signaling pathways, cell proliferation, apoptosis, migration and invasion and oncogenesis (Brennan et al., 2007; Cooper et al., 2018; Nava et al., 2007). Loss of DSG2 function in humans is directly linked to arrhythmogenic right ventricular cardiomyopathy (ARVC), an autosomal recessive disease underpinned by myocyte apoptosis and fibrous degeneration of the myocardium (Pilichou et al., 2009). Studies showed that DSG2 was aberrantly expressed in many tumors, such as gastric cancer (Biedermann et al., 2005), skin squamous cell carcinomas (Kurzen, Munzing & Hartschuh, 2003) and melanoma (Tan et al., 2016). Trojan et al revealed that increased expression of DSG2 was found in the metastatic prostate cancer cell line compared to its non-metastatic syngeneic precursor cell (Trojan et al., 2005).

Moreover, DSG2 has an impact on the occurrence and development of many tumors and is closely related with diagnosis and prognosis of cancers. For instance, Davie et al reported that DSG2 was a putative tumor suppressor and could reduce cell aggregation, invasion, and motility in human breast cancer cells (Davies et al., 1997). Another study revealed that reduced level of DSG2 was a significant independent marker of poor clinical outcome (Barber et al., 2014). To date, few studies have reported that DSG2 might be an early diagnostic and independent prognostic marker for lung adenocarcinoma (Cai et al., 2017; Saaber et al., 2015). The molecular mechanisms of DSG2 in lung adenocarcinoma remain largely elusive and require further investigation.
In this study, the clinical value of DSG2 was evaluated. Firstly, a total of 40 paired lung adenocarcinoma tissues and corresponding non-cancerous tissues were used to detect the expression of DSG2. Data from The Cancer Genome Atlas (TCGA) and Oncomine datasets were also downloaded and analyzed. The expression level of DSG2 protein by immunohistochemical was also detected by the tissue microarray and the Human Protein Atlas (HPA) database. The correlation between DSG2 and clinicopathological features was investigated. Secondly, integrated meta-analysis was performed to evaluate the clinical value of DSG2. Survival analysis was evaluated by univariate and multivariate Cox regression analyses. Thirdly, co-expressed genes were calculated by Pearson correlation analysis. Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were used to investigate the underlying molecular mechanism. The expression between LUAD and normal lung tissues and prognostic significance of the top ten co-expressed genes were searched from Gene Expression Profiling Interactive Analysis (GEPIA) online database.

MATERIAL AND METHODS

Patients and tissues

Forty paired lung adenocarcinoma tissues and non-cancer tissues (>five cm adjacent to the tumor) were collected from patients who underwent pulmonary surgery in the department of thoracic surgery in our hospital from March 2016 to June 2019. All patients had no history of other cancers and underwent no other prior treatment including chemotherapy, radiotherapy or targeted therapy before surgery. This study was approved by the Ethics Committee of the Second Affiliated Hospital of Xi’an Jiaotong University (2016036). Written informed consent was obtained from all participants.

Tissue microarray (TMA) and immunohistochemistry

Tissue microarray (HLugA150CS03) containing 75 paired lung adenocarcinoma tissues and adjacent non-tumor tissues was purchased from Shanghai Outdo Biotech (Shanghai, China). Then immunohistochemistry (IHC) assay was performed. Tissue sections were treated with EDTA buffer under high pressure at high temperature to retrieve antigen. Sections were incubated with primary antibody DSG2 (1:250, ab150372, Abcam, USA) at 4 °C overnight. Biotinylated anti-IgG was added and incubated at room temperature for 1 hour. The slides were stained with DAB and counterstained with haematoxylin after incubating with streptomyein-HRP for 30 minutes. Samples were visualized using diaminobenzidine system and hematoxylin re-dying, and analyzed under microscope (OLYMPUS CX41, Japan).

Tissue microarrays were scored independently by two pathologists who were blinded to the clinicopathologic features and outcomes of the patients. The staining was analyzed under low magnification (40×) and high magnification (200×). The intensity of staining was divided into four grades (intensity scores): negative (0), weak (1), moderate (2) and strong (3). Immunoreactivity was divided into five grades (percentage scores) according to the percentage of stained cells: no staining (0), 1%–25% (1), 26%–50% (2), 51%–75% (3) and >75% (4). Then, a final histological overall score was calculated by the multiplication

Sun et al. (2020), PeerJ, DOI 10.7717/peerj.8420
of the two values. An overall score of 0–12 was calculated and graded as low (score < 7) or high (score ≥ 7).

**Qrt-pcr**

Fast1000 (Xfyangbio, China) was used to extract the total RNA from all the specimens according to the manufacturer’s protocol. After the reverse transcription, the TB Green® Premix Ex Taq™ II (Takara Biotechnology Co., Ltd.) was utilized to detect the gene amplification and qRT-PCR was performed on the CFX96 Touch™ Real-Time PCR Detection System (Bio-rad) in standard mode for 40 cycles. The primers were as follows: ACTIN forward, 5′-TGGCACCCAGCACAATGAA-3′ and reverse, 5′-CTAAGTCATAGTCCGCTAGAAGCA-3′; DSG2 forward, 5′-ATGACGGCTAGGAACACCAC-3′ and reverse, 5′-GGGTCAGTTTGTGGCTGACT-3′ (Vite et al., 2013).

All experiments were conducted in triplicate. The difference of DSG2 expression between cancer tissues and non-cancer tissues was calculated using the formula $2^{-\Delta Cq}$.

**Data from online databases**

RNA-Seq data of DSG2 in LUAD were downloaded from TCGA (https://portal.gdc.cancer.gov/). After repeated values were deleted, LUAD consisted of 513 lung adenocarcinoma tissues and 59 lung normal tissues. Among them, there were 57 paired tissues. The original expression data were displayed in fragments per kilobase million (FPKM). All the data were transformed into TPM (transcripts per million reads) and normalized by log2(TPM+1) for the following analyses. Clinical information including age, gender, tumor-node-metastasis (TNM) stage, smoking status were also obtained. The original data from other studies were downloaded from Oncomine database (http://www.oncomine.org/). Also, the expression level of DSG2 protein was detected from the Human Protein Atlas (http://www.proteinatlas.org/) (Ponten, Jirstrom & Uhlen, 2008).

**Integrated meta-analysis**

A comprehensive meta-analysis was performed to determine the combined expression value of DSG2 in LUAD groups and non-cancer groups by combining the three sources (qRT-PCR data, TCGA data and Oncomine datasets). I-squared test was used to evaluate heterogeneity. When $I^2<50\%$, a fixed-effects model was used, while $I^2>50\%$, the random-effects model was selected (Higgins et al., 2003). Standard mean difference (SMD) with a 95% confidential interval (CI) was used to assess the effect sizes of these pooled data. A summary receiver operating characteristic (SROC) curve was constructed to describe the diagnostic ability of DSG2 in LUAD. In addition, Begg’s test was carried out to confirm whether publication bias existed in the studies.

**Co-expressed genes and pathways identification and analysis**

In order to find out potential mechanism, Pearson test was used to identify co-expressed genes. The cutoff value was set as $|R|>0.4$ and $P < 0.05$. The interaction between DSG2 and co-expressed genes were processed by the Cytoscape 3.7.1 software to generate a visual image. GO enrichment and KEGG pathway analysis of these co-expressed genes were performed by Database for Annotation, Visualization and Integrated Discovery.
DAVID online database (https://david.ncifcrf.gov/) (Huang da, Sherman & Lempicki, 2009). P < 0.05 and false discovery rate (FDR) <0.05 were considered to have significance significantly. GEPIA (http://gepia.cancer-pku.cn/index.html) contains the RNA sequencing expression data of 9,736 tumors and 8,587 normal cases from TCGA and the Genotype-Tissue Expression (GTEx) projects (Tang et al., 2017). In the present study, GEPIA was used to compare the expression levels of the co-expressed genes between lung adenocarcinoma tissues and normal tissues and investigate the prognostic significance.

Statistical analysis
All data were analyzed using R software (version 3.5.1) and GraphPad Prism 8. Meta-analysis was analyzed using STATA 15. The student’s t-test was used to compare the differential expression level of DSG2 between LUAD tissues and adjacent normal lung tissues. The associations between the level of DSG2 and clinicopathological parameters were evaluated using Mann-Whitney U test or Kruskal–Wallis H test. The chi-squared test was utilized to determine whether there was a difference in the distribution of DSG2 samples among the different categories in the TMA. The prognostic value was evaluated by Cox regression analyses and Kaplan–Meier. Multivariate Cox analysis was used to compare the impact of DSG2 expression on survival along with other clinical traits, the median DSG2 expression was regarded as the cut-off value. The associations between DSG2 expression and co-expressed genes were determined by Pearson correlation coefficient. All p value <0.05 was considered statistically significant.

RESULTS
Clinical value of DSG2 expression in lung adenocarcinoma
In the current study, a total of 40 paired lung adenocarcinoma samples were utilized to determine the expression of DSG2 by qRT-PCR. As shown in Fig. 1A, DSG2 was significantly over-expressed in lung adenocarcinoma than corresponding non-tumorous normal tissues (p < 0.001). To further identify the importance of DSG2 in the lung adenocarcinoma progression, the correlation between DSG2 and clinicopathological features was analyzed. The expression level of DSG2 in patients with early TNM tumor stage (I–II) was lower than patients with advanced TNM stage (III–IV) (0.063 ± 0.040 vs 0.128 ± 0.098, p = 0.023). For tumors greater than three cm in size, a significant increase in DSG2 expression was observed (0.109 ± 0.087 vs 0.052 ± 0.027, p = 0.027). Patients with lymph node metastasis exhibited higher DSG2 expression than patients without lymph node metastasis (0.113 ± 0.087 vs 0.053 ± 0.034, p = 0.014). No significant association was found between DSG2 expression and other clinicopathological characteristics, including age, gender and smoking history (Table 1).

To further verify our results, data from other studies including TCGA data and Oncomine datasets were used. Original data consisted of 513 LUAD samples and 59 normal lung samples with clinicopathological information were downloaded from TCGA. Among them, there were 57 paired LUAD samples. As shown in Fig. 1B, increased expression of DSG2 was observed in cancer tissues compared to normal lung tissues (p < 0.001). The analysis of the paired LUAD samples exhibited a consistently higher expression level
in lung cancer (Fig. 1C). In addition, the associations between DSG2 expression and clinicopathological parameters were shown in Table 2. A higher expression of DSG2 is significantly correlated with a higher T stage \((p = 0.001)\), N stage \((p < 0.001)\) and TNM stage \((p < 0.001)\). Also, the expression of DSG2 was closely related with gender \((p = 0.017)\). With regard to age, smoking history and M stage, no statistical significance was observed. Nine datasets about LUAD were downloaded from Oncomine online database. In all the studies, DSG2 has a significant higher expression in cancer tissues than lung normal tissues (Figs. 1D–1L).

In addition, tissue microarray was used to verify the expression level of DSG2. The system scoring was shown in Figs. 2A–2I. Immunohistochemistry staining analysis showed higher expression of DSG2 in LUAD tissues compared with the adjacent non-tumor tissues (Figs. 2J–2K, \(p < 0.001)\). Higher DSG2 expression was positively associated lymph node metastasis \((p = 0.040)\). However, there was no correlation between DSG2 expression and age, tumor size or TNM stage (Table 3, \(p > 0.05)\). Higher DSG2 expression was also
### Table 1  Correlation between the expression of DSG2 and the clinicopathological characteristics of the lung adenocarcinoma patients.

| Clinicopathological features          | n    | Mean ± SD   | p-value |
|--------------------------------------|------|-------------|---------|
| Age (years)                          |      |             |         |
| <60                                  | 23   | 0.089 ± 0.074 | 0.845  |
| ≥60                                  | 17   | 0.092 ± 0.084 |         |
| Gender                               |      |             |         |
| Male                                 | 18   | 0.080 ± 0.058 | 0.973  |
| Female                               | 22   | 0.099 ± 0.090 |         |
| Smoking history                      |      |             |         |
| No                                   | 24   | 0.099 ± 0.086 | 0.759  |
| Yes                                  | 16   | 0.077 ± 0.058 |         |
| TNM tumor stage                      |      |             |         |
| I+II                                 | 23   | 0.063 ± 0.040 | 0.023* |
| III+IV                               | 17   | 0.128 ± 0.098 |         |
| Tumor size (cm)                      |      |             |         |
| ≤3                                   | 13   | 0.052 ± 0.027 | 0.027* |
| >3                                   | 27   | 0.109 ± 0.087 |         |
| Lymph node metastasis                |      |             |         |
| No                                   | 15   | 0.053 ± 0.034 | 0.014* |
| Yes                                  | 25   | 0.113 ± 0.087 |         |

**Notes.**

* *p < 0.05; TNM, tumor-node-metastasis; SD, standard deviation.

### Table 2  Relationship between the expression of DSG2 and clinicopathological features in LUAD based on the TCGA.

| Clinicopathological features          | n    | Mean ± SD   | p-value |
|--------------------------------------|------|-------------|---------|
| Age (years)                          |      |             |         |
| <60                                  | 136  | 6.441 ± 1.233 | 0.419  |
| ≥60                                  | 358  | 6.360 ± 1.084 |         |
| Gender                               |      |             |         |
| Male                                 | 237  | 6.488 ± 1.180 | 0.017* |
| Female                               | 276  | 6.283 ± 1.099 |         |
| Smoking history                      |      |             |         |
| No                                   | 12   | 6.648 ± 0.987 | 0.439  |
| Yes                                  | 499  | 6.374 ± 1.145 |         |
| T                                     |      |             |         |
| T1                                   | 168  | 6.156 ± 1.041 | 0.001**|
| T2                                   | 276  | 6.436 ± 1.251 |         |
| T3                                   | 47   | 6.589 ± 0.776 |         |
| T4                                   | 19   | 6.898 ± 0.697 |         |
| N                                     |      |             |         |
| N0                                   | 330  | 6.236 ± 1.180 | <0.001**|
| N1                                   | 95   | 6.538 ± 1.016 |         |
| N2                                   | 74   | 6.823 ± 1.047 |         |
| M                                     |      |             |         |
| M0                                   | 344  | 6.423 ± 1.109 | 0.786  |
| M1                                   | 25   | 6.473 ± 0.804 |         |
| TNM tumor Stage                      |      |             |         |
| I                                     | 274  | 6.173 ± 1.193 | <0.001**|
| II                                    | 121  | 6.522 ± 1.096 |         |
| III                                   | 84   | 6.798 ± 1.010 |         |
| IV                                    | 26   | 6.500 ± 0.801 |         |

**Notes.**

* *p < 0.05.

** *p < 0.01.

T, tumor; N, node; M, metastasis; TNM, tumor-node-metastasis; SD, standard deviation.
observed in the male group than the female group ($p < 0.001$). DSG2 was located in the cytoplasm or membranous. Moreover, immunostaining evidence from the Human Protein Atlas database supported the upregulation of DSG2 in lung adenocarcinoma tissues. Two different antibodies (HPA004896 and CAB025122) were utilized to detect the expression of DSG2 in 9 lung adenocarcinoma tissues and 6 normal lung tissues. By antibody CAB025122, 3 were high staining and 2 were medium. By using antibody HPA004896, of total 4 lung adenocarcinoma tissues, 3 were high staining and 1 was medium. However, staining in normal lung tissues were both low no matter which antibody was used (Figs. 2L–2O).
Table 3  Association between the DSG2 expression in LUAD tissues and the patients’ clinical characteristics based on the tissue microarray.

| Clinicopathological features | n     | DSG2 expression | p-value |
|------------------------------|-------|-----------------|---------|
|                              |       | Low | High |       |        |
| Tissues                      | 60    | 60  | 0    | 62    | 33  | 29  | <0.000** |
| Age (years)                  |       |     |      |       |      |     |   |
| <60                          | 27    | 14  | 13   | 35    | 19  | 16  | 0.849 |
| ≥60                          |       |     |      |       |      |     |   |
| Gender                       |       |     |      |       |      |     |   |
| Male                         | 32    | 10  | 22   | 29    | 22  | 7   | <0.001** |
| Female                       |       |     |      |       |      |     |   |
| T                            |       |     |      |       |      |     |   |
| T1                           | 10    | 8   | 2    | 52    | 25  | 27  | 0.064 |
| T2-3                         |       |     |      |       |      |     |   |
| N                            |       |     |      |       |      |     |   |
| N0                           | 31    | 21  | 10   | 29    | 12  | 17  | 0.040 |
| N1-3                         |       |     |      |       |      |     |   |
| TNM tumor Stage              |       |     |      |       |      |     |   |
| I-II                         | 37    | 23  | 14   | 25    | 10  | 15  | 0.086 |
| III-IV                       |       |     |      |       |      |     |   |

Notes.
*p < 0.05.
**p < 0.01.

T, tumor; N, node; TNM, tumor-node-metastasis.

Integrated meta-analysis

The results of the integrated meta-analysis contained TCGA data, Oncomine datasets and qRT-PCR data. As shown in Fig. 3A, the pooled effect sizes from forest plots indicated that DSG2 was significantly highly expressed in lung adenocarcinoma than in non-cancer tissues (SMD=1.30, 95% CI [1.08–1.52], p = 0.014) using the random effect model (I²=54.8%). Area under curve (AUC) for the diagnostic value of DSG2 was 0.79 (95% CI [0.75–0.82]) (Fig. 3B). The pooled sensitivity and specificity were 0.73 (95% CI [0.69–0.76]) (Fig. 3C) and 0.96 (95% CI [0.89–0.98]) (Fig. 3D), respectively. Apart from that, Begg’s test revealed that no publication bias existed among all the studies analyzed (p = 0.615).

Survival analysis

To evaluate the relationship between DSG2 and prognosis, Kaplan–Meier survival analysis was performed. The exclusion criteria were overall survival of <30 days. The expression of DSG2 was cut into high expression level and low expression level according to the median value of DSG2. As the result shown in Fig. 4, high mRNA expression of DSG2 was associated with shorter overall survival (hazard ratio [HR]: 1.638; 95% CI [1.214–2.209], p = 0.001) and poor progression-free survival (HR: 1.475; 95% CI [1.102–1.974], p < 0.001). Furthermore, multivariate Cox regression analysis was performed to explore factors associated with survival. A trend was observed in which low DSG2 expression was associated with an increased survival time. However, no statistical significance was determined (Table 4).

Co-expressed genes and potential pathways associated with DSG2

Based on TCGA, 215 co-expressed genes with DSG2 were identified (Fig. 5). Then GO enrichment analysis and KEGG pathway analysis were processed. As the result shown in Fig. 6 and Table 5, those co-expressed genes were mainly enriched in ‘cell division’, ‘mitotic
nuclear division’, ‘chromosome segregation’ in Biological Process; ‘cytosol’, ‘midbody’ and ‘membrane’ in Cellular Component; ‘ATP binding’, ‘protein binding’, ‘microtubule motor activity’ in Molecular Function. KEGG pathway analysis revealed a significant enrichment of the co-expressed genes in the pathway ‘cell cycle’. The ten genes most strongly correlated with DSG2 are DSC2, SLC2A1, BZW1, ARNTL2, ERO1L, CLDN12, ECT2, ANLN, LAMC2 and GPR115. The expression and the correlation with OS of these ten genes were validated from GEPIA database. The results showed that seven of ten co-expressed genes were both significantly higher in LUAD compared to normal lung tissues and with worse OS (DSC2, SLC2A1, ARNTL2, ERO1L, ECT2, ANLN and LAMC2) (Fig. 7).

In order to determine whether DSG2 plus the co-expressed genes could generate a synergistic effect for OS, all gene data were downloaded from TCGA. The expression of each gene was cut into high expression level and low expression level. Cox analyses were performed to calculate the HR. Unfortunately, HR of DSG2 +DSC2 was lower than
Figure 4  Survival analysis of DSG2 in LUAD. Patients with high DSG2 expression had a significantly short overall survival (A) and poor progression free survival (B) in TCGA. 

Table 4  Univariate and multivariate analyses of overall survival in TCGA.

| Parameters           | Univariate analysis | Multivariate analysis |
|----------------------|---------------------|-----------------------|
|                      | p-value  | HR     | 95% CI | p-value | HR     | 95% CI |
| Age                  | 0.755    | 1.054  | 0.756  | 1.470   |        |        |
| Gender               | 0.588    | 0.922  | 0.697  | 1.237   |        |        |
| Smoking history      | 0.258    | 0.690  | 0.363  | 1.312   |        |        |
| TNM tumor stage      | <0.001** | 1.694  | 1.472  | 1.948   | 0.068  | 1.458  | 0.973  | 2.186  |
| T                    | <0.001** | 1.547  | 1.283  | 1.866   | 0.072  | 1.231  | 0.982  | 1.544  |
| N                    | <0.001** | 1.709  | 1.438  | 2.030   | 0.285  | 1.214  | 0.851  | 1.731  |
| M                    | 0.003**  | 2.257  | 1.316  | 3.869   | 0.621  | 0.775  | 0.282  | 2.128  |
| DSG2                 | 0.001**  | 1.638  | 1.214  | 2.209   | 0.461  | 1.151  | 0.792  | 1.673  |

Notes.  
**p < 0.01.  
T, tumor; N, node; M, metastasis; TNM, tumor-node-metastasis; HR, hazard ratio; CI, confidence interval.

DSG2 or DSC2 alone (1.349 vs 1.638 vs 1.645). There was no synergistic effect when DSG2 combined with the co-expressed genes. This phenomenon was also found in other six genes (SLC2A, ARTNL2, ERO1L, ECT2, ANLN and LAMC2) (Table 6).

DISCUSSION

In this study, we have investigated the clinical value of DSG2 in lung adenocarcinoma. Quantitative RT-PCR data, TCGA data and Oncomine datasets were utilized to validate the high expression of DSG2 in lung adenocarcinoma. The expression of DSG2 protein was also higher in lung adenocarcinoma by tissue microarray and HPA database. In order to explore the role of DSG2 in the development of lung adenocarcinoma, the relationship between DSG2 and the clinicopathological parameters were analyzed. We found that high DSG2 expression was positively correlated with TNM stage, tumor size, lymph node metastasis and poor prognosis of LUAD patients. Pearson analysis was used to detect co-expressed genes with DSG2 in LUAD. Seven of top ten genes showed high expression in
Figure 5 A total of 215 co-expressed genes were processed by the Cytoscape 3.7.1 software to generate a visual image based on LUAD. Blue dots represent $0.5 > |R| > 0.4$. Red dots represent $|R| \geq 0.5$. The size of the dots represents $p$-value. The smaller the $p$-value, the larger the dot.

LUAD according to GEPIA database. High expression of these genes had a shorter overall survival time.

Multiple studies have shown that DSG2 is deregulated in many types of human tumors. Because of the heterogeneity of cancers, its expression trends are not the same in different tumors. For example, DSG2 is over-expressed in malignant skin carcinomas (Brennan & Mahoney, 2009) and low-expressed in pancreatic cancer (Ramani, Hennings & Haun, 2008). Saaber et al. (2015) detected DSG2 protein expression in 112 primary lung cancer samples (including 82 LUSC cases and 22 LUAD cases) by IHC and found that the expression of DSG2 was significantly higher in LUSC than in LUAD ($p = 0.009$). Cai et al. (2017) detected the DSG2 expression in 28 paired NSCLC and normal tissue samples by qRT-PCR and in 70 cases of paraffin-embedded NSCLC tissues. The results demonstrated that both DSG2 mRNA and protein were highly expressed in NSCLC. These findings were
Figure 6  GO analysis of the co-expressed genes with DSG2 in LUAD. The bubble size represents the number of genes in one GO term. The more genes, the larger the bubble size. The horizontal axis $z$-score was calculated by the formula $z$-score = (up–down)/ $\sqrt{\text{count}}$, up represent the number of over-expressed genes in one term, down represent the number of low-expressed genes, count means the total of genes. The GO enrichment analysis in BP were showed in green bubbles (A), CC were showed in red bubbles (B), MF were showed in blue bubbles (C). BP, Biological process; CC, Cellular Component; MF, Molecular function.

consistent with our study. Interestingly, our previous studies also demonstrated that DSG2 was over-expressed in NSCLC. In 2014, we investigated a differential expression profile between lung adenocarcinoma and normal lung tissue by iTRAQ labeling combined with 2D-LC-MS/MS. Bioinformatic analysis showed that DSG2 was 1.5-fold higher in lung adenocarcinoma than normal lung tissue (Zhang et al., 2014). In 2016, we investigated differences in the mitochondrial protein profiles between lung adenocarcinomas and normal tissue. Differentially expressed proteins were identified and DSG2 was one of them (Li et al., 2017).

It has been reported that desmosomal cadherin related genes play an important role in the proliferation and metastasis of many human cancers in recent years (Ormanns et al., 2015; Wang et al., 2016; Yang et al., 2015). DSG2 is also involved in the occurrence, development and metastasis of tumors. However, the roles in different tumors are not the same. DSG2 present in breast cancer cells may function as a tumor suppressor molecule (Davies et al., 1997). In pancreatic adenocarcinoma cells, silencing of DSG2 resulted in loss of cell cohesion and improved migration and invasion (Hutz et al., 2017). However, in
### Table 5  GO enrichment and KEGG analysis of the co-expressed genes with DSG2 in LUA.

| Category/term | Count | p-value | FDR  |
|---------------|-------|---------|------|
| Biological process | | | |
| GO: 0051301 ~cell division | 26 | 0.074 | <0.001 |
| GO: 0007067 ~mitotic nuclear division | 22 | 0.063 | <0.001 |
| GO: 0007059 ~chromosome segregation | 10 | 0.029 | <0.001 |
| GO: 0007062 ~sister chromatid cohesion | 11 | 0.031 | <0.001 |
| GO: 0007018 ~microtubule-based movement | 9 | 0.026 | 0.005 |
| GO: 0019886 ~antigen processing and presentation of exogenous peptide antigen via MHC class II | 9 | 0.026 | 0.013 |
| Cellular component | | | |
| GO: 0005829 ~cytosol | 73 | <0.001 | <0.001 |
| GO: 0030496 ~midbody | 14 | <0.001 | <0.001 |
| GO: 0016020 ~membrane | 54 | <0.001 | <0.001 |
| GO: 0005737 ~cytoplasm | 91 | <0.001 | <0.001 |
| GO: 0005730 ~nucleolus | 28 | <0.001 | <0.001 |
| GO: 0005813 ~centrosome | 19 | <0.001 | 0.001 |
| GO: 0051233 ~spindle midzone | 6 | <0.001 | 0.002 |
| GO: 0005871 ~kinesin complex | 8 | <0.001 | 0.002 |
| GO: 0000776 ~kinetochore | 9 | <0.001 | 0.004 |
| GO: 0000922 ~spindle pole | 10 | <0.001 | 0.004 |
| Molecular function | | | |
| GO: 0005524 ~ATP binding | 42 | <0.001 | <0.001 |
| GO: 0005515 ~protein binding | 133 | <0.001 | <0.001 |
| GO: 0003777 ~microtubule motor activity | 9 | <0.001 | 0.004 |
| GO: 0008017 ~microtubule binding | 13 | <0.001 | 0.006 |
| GO: 0008574 ~ATP-dependent microtubule motor activity, plus-end-directed | 5 | <0.001 | 0.044 |
| Pathway | | | |
| hsa04110: Cell cycle | 11 | <0.001 | 0.002 |

**Notes.**
FDR, false discovery rate; hsa, Homo sapiens.

Colon cancers and NSCLC, knockdown DSG2 suppressed cell proliferation both in vitro and in vivo. DSG2 functions through many ways. Downregulation of DSG2 inhibited cell proliferation through altered phosphorylation of epidermal growth factor receptor (EGFR) and downstream extracellular signal-regulated kinase activation (Kamekura et al., 2014). Further study shows that overexpression of DSG2 in human skin squamous cell carcinoma cell line enhances EGFR activation and increases cell proliferation and migration through a c-Src and EGFR dependent manner (Overmiller et al., 2016). DSG2 knockdown also downregulated cyclin-dependent kinase 2 expression and upregulated p27 expression in NSCLC (Cai et al., 2017). A recent study showed that overexpression of DSG2 induced STAT3 phosphorylation and further increased Gli1 levels in basal cell carcinomas (Brennan-Crispi et al., 2019).
Figure 7  The expression and survival analysis of the co-expressed genes from GEPIA online database. In each box-and-whiskers plot, the red box represents the LUAD tissues and the grey box represents the normal lung tissues. The expression of DSC2 (A), SLC2A1 (C), ARNTL2 (E), ERO1L (G), ECT2 (I), ANLN (K), LAMC2 (M) was highly expressed in LUAD compared to normal lung tissues. High expression of DSC2 (B), SLC2A1 (D), ARNTL2 (F), ERO1L (H), ECT2 (J), ANLN (L), LAMC2 (N) had shorter overall survival. $p < 0.05$.  

Full-size DOI: 10.7717/peerj.8420/fig-7
### Table 6  Overall survival analysis of DSG2 combined with the co-expressed genes based on TCGA.

| Gene          | p-value  | HR   | 95% CI       |
|---------------|----------|------|--------------|
| DSG2          | 0.001**  | 1.638| 1.214 2.209  |
| DSC2          | 0.001**  | 1.645| 1.219 2.22   |
| DSG2+DSC2     | <0.001** | 1.349| 1.144 1.591  |
| SLC2A1        | <0.001** | 1.864| 1.378 2.522  |
| DSG2+SLC2A1   | <0.001** | 1.436| 1.210 1.705  |
| ARNTL2        | 0.002**  | 1.601| 1.187 2.159  |
| DSG2+ARNTL2   | <0.001** | 1.397| 1.171 1.667  |
| ERO1L         | <0.001** | 1.921| 1.421 2.596  |
| DSG2+ERO1L    | <0.001** | 1.501| 1.255 1.795  |
| ECT2          | <0.001** | 1.739| 1.289 2.348  |
| DSG2+ECT2     | <0.001** | 1.436| 1.204 1.713  |
| ANLN          | <0.001** | 2.007| 1.485 2.713  |
| DSG2+ANLN     | <0.001** | 1.508| 1.264 1.799  |
| LAMC2         | 0.015*   | 1.445| 1.074 1.944  |
| DSG2+LAMC2    | <0.001** | 1.337| 1.125 1.590  |

**Notes.**

*p < 0.05.

**p < 0.01.

HR, hazard ratio; CI, confidence interval.

DSG2 can be a prognostic marker in cancers. Reduced level of DSG2 was a significant independent marker of poor clinical outcome in prostate cancer (Barber et al., 2014). On the contrary, increased DSG2 expression may function as a promising marker for unfavorable prognosis of hepatocellular carcinoma (Han et al., 2018). In our study, DSG2 might be an independent risk factor for lung adenocarcinoma.

DSG2 is closely related to DSC2. Lie, Cheng & Mruk (2010) proposed a novel regulatory protein complex composed DSG2, DSC2, c-Src, coxsackie and adenovirus receptor and ZO-1 at the blood-testis barrier. Another study showed that DSC2 was compensatory increased in DSG2-deficient cells, while downregulated DSC2 restored proliferation in DSG2-deficient cells (Kamekura et al., 2014). Besides DSC2, we found six genes (SLC2A, ARNTL2, ERO1L, ECT2, ANLN, LAMC2) were co-expressed with DSG2 in LUAD. Solute carrier family 2 (SLC2A) is a uniporter protein encoded by the SLC2A1 gene and functions as a pivotal rate-limiting element in the transport of glucose in tumor cells (Zhang, Xie & Li, 2019). ARNTL2 is a paralog of the circadian transcription factor ARNTL1 and drives metastatic self-sufficiency by orchestrating the expression of a complex pro-metastatic secretome in lung adenocarcinoma (Brady et al., 2016). Endoplasmic reticulum oxidoreductase 1 alpha (ERO1L) is an endoplasmic reticulum (ER) luminal glycoprotein and favors disulfide bond formation by selectively oxidizing PDI (Cabibbo et al., 2000). Epithelial cell transforming sequence 2 (ECT2) is a guanine nucleotide exchange factor (GEF) of the Rho GTPase family. It regulates cell division and cell cycle (Wang et al., 2018). Anillin (ANLN) encodes an actin-binding protein that consists of 1125 amino acids and plays an important role in cytokinesis (Wang et al., 2019). Laminin γ2 (LAMC2), LAMB3...
and LAMA3 constitutes the heterotrimeric glycoprotein laminin-332, then regulate the migration of epithelial cells and promote cancer invasion (Masuda et al., 2012). To date, no studies on these genes and DSG2 could be found.

In order to explore the potential mechanism of the 215 co-expressed genes, GO and KEGG enrichment analysis were performed. According to GO enrichment, the co-expressed genes correlated with DSG2 might have an important effect on the progression of LUAD by modulating several cellular biology processes, such as cell division. Moreover, these genes might be closely related with cell cycle related pathway. More studies are needed in the future.

**CONCLUSION**

All in all, our data showed that the mRNA and protein levels of DSG2 were enhanced in LUAD. High expression of DSG2 was positively associated with TNM stage, tumor size and lymph node metastasis. LUAD patients with high DSG2 expression had shorter overall survival and poor progression-free survival. Co-expressed genes correlated with DSG2 were mainly enriched in ‘cell division’, ‘mitotic nuclear division’, ‘chromosome segregation’ in BP; ‘cytosol’, ‘midbody’ and ‘membrane’ in CC; ‘ATP binding’, ‘protein binding’, ‘microtubule motor activity’ in MF; ‘cell cycle’ in KEGG pathway analysis. Further studies are still needed to investigate the potential mechanism of DSG2 in LUAD.

**ADDITIONAL INFORMATION AND DECLARATIONS**

**Funding**
The study was supported by grants from the National Natural Science Foundation of China (No. 81672300). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Grant Disclosures**
The following grant information was disclosed by the authors:
National Natural Science Foundation of China: 81672300.

**Competing Interests**
The authors declare there are no competing interests.

**Author Contributions**
- Ruiying Sun performed the experiments, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
- Chao Ma analyzed the data, prepared figures and/or tables, and approved the final draft.
- Wei Wang analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.
- Shuanying Yang conceived and designed the experiments, authored or reviewed drafts of the paper, and approved the final draft.
Human Ethics
The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):
This study was approved by the Ethics Committee of the second affiliated hospital of Xi’an Jiaotong University (2016036).

Data Availability
The following information was supplied regarding data availability:
The raw measurements are available in the Supplementary Files.

Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.8420#supplemental-information.

REFERENCES
Barber AG, Castillo-Martin M, Bonal DM, Rybicki BA, Christiano AM, Cordon-Cardo C. 2014. Characterization of desmoglein expression in the normal prostatic gland. Desmoglein 2 is an independent prognostic factor for aggressive prostate cancer. PLOS ONE 9:e98786 DOI 10.1371/journal.pone.0098786.

Biedermann K, Vogelsang H, Becker I, Plaschke S, Siewert JR, Hofler H, Keller G. 2005. Desmoglein 2 is expressed abnormally rather than mutated in familial and sporadic gastric cancer. Journal of Pathology 207:199–206 DOI 10.1002/path.1821.

Brady JJ, Chuang CH, Greenside PG, Rogers ZN, Murray CW, Caswell DR, Hartmann U, Connolly AJ, Sweet-Cordero EA, Kundaje A, Winslow MM. 2016. An Arntl2-driven secretome enables lung adenocarcinoma metastatic self-sufficiency. Cancer Cell 29:697–710 DOI 10.1016/j.ccell.2016.03.003.

Brennan D, Hu Y, Joubeh S, Choi YW, Whitaker-Menezes D, O’Brien T, Uitto J, Rodeck U, Mahoney MG. 2007. Suprabasal Dsg2 expression in transgenic mouse skin confers a hyperproliferative and apoptosis-resistant phenotype to keratinocytes. Journal of Cell Science 120:758–771 DOI 10.1242/jcs.03392.

Brennan D, Mahoney MG. 2009. Increased expression of Dsg2 in malignant skin carcinomas: a tissue-microarray based study. Cell Adhesion & Migration 3(2):148–154 DOI 10.4161/cam.3.2.7539.

Brennan–Crispi DM, Overmiller AM, Tamayo-Orrego L, Marous MR, Sahu J, McGuinn KP, Cooper F, Georgiou IC, Frankfurter M, Salas-Alanis JC, Charron F, Millar SE, Mahoney MG, Riobo-Del Galdo NA. 2019. Overexpression of desmoglein 2 in a mouse model of gorlin syndrome enhances spontaneous basal cell carcinoma formation through STAT3-mediated gil1 expression. Journal of Investigative Dermatology 139:300–307 DOI 10.1016/j.jid.2018.09.009.

Cabibbo A, Pagani M, Fabbri M, Rocchi M, Farmery MR, Bulleid NJ, Sitia R. 2000. ERO1-L, a human protein that favors disulfide bond formation in the endoplasmic reticulum. Journal of Biological Chemistry 275:4827–4833 DOI 10.1074/jbc.275.7.4827.
Cai F, Zhu Q, Miao Y, Shen S, Su X, Shi Y. 2017. Desmoglein-2 is overexpressed in non-small cell lung cancer tissues and its knockdown suppresses NSCLC growth by regulation of p27 and CDK2. *Journal of Cancer Research and Clinical Oncology* 143:59–69 DOI 10.1007/s00432-016-2250-0.

Cooper F, Overmiller AM, Loder A, Brennan-Crispi DM, McGuinn KP, Marous MR, Freeman TA, Riobo-Del Galdo NA, Siracusa LD, Wahl 3rd JK, Mahoney MG. 2018. Enhancement of cutaneous wound healing by Dsg2 augmentation of uPAR secretion. *Journal of Investigative Dermatology* 138:2470–2479 DOI 10.1016/j.jid.2018.04.024.

Davies E, Cochrane R, Hiscox S, Jiang W, Sweetland H, Mansel R. 1997. The role of desmoglein 2 and E-cadherin in the invasion and motility of human breast cancer cells. *International Journal of Oncology* 11:415–419.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *International Journal of Cancer* 127:2893–2917 DOI 10.1002/ijc.25516.

Han CP, Yu YH, Wang AG, Tian Y, Zhang HT, Zheng ZM, Liu YS. 2018. Desmoglein-2 overexpression predicts poor prognosis in hepatocellular carcinoma patients. *European Review for Medical and Pharmacological Sciences* 22(17):5481–5489 DOI 10.26355/eurrev_201809_15808.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. 2003. Measuring inconsistency in meta-analyses. *BMJ* 327:557–560 DOI 10.1136/bmj.327.7414.557.

Huang da W, Sherman BT, Lempicki RA. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nature Protocols* 4:44–57 DOI 10.1038/nprot.2008.211.

Hutz K, Zeiler J, Sachs L, Ormanns S, Spindler V. 2017. Loss of desmoglein 2 promotes tumorigenic behavior in pancreatic cancer cells. *Molecular Carcinogenesis* 56:1884–1895 DOI 10.1002/mc.22644.

Kamekura R, Kolegraff KN, Nava P, Hilgarth RS, Feng M, Parkos CA, Nusrat A. 2014. Loss of the desmosomal cadherin desmoglein-2 suppresses colon cancer cell proliferation through EGFR signaling. *Oncogene* 33:4531–4536 DOI 10.1038/onc.2013.442.

Kurzen H, Munzing I, Hartschuh W. 2003. Expression of desmosomal proteins in squamous cell carcinomas of the skin. *Journal of Cutaneous Pathology* 30:621–630 DOI 10.1034/j.1600-0650.2003.00122.x.

Li W, Zhang X, Wang W, Sun R, Liu B, Ma Y, Zhang W, Ma L, Jin Y, Yang S. 2017. Quantitative proteomics analysis of mitochondrial proteins in lung adenocarcinomas and normal lung tissue using iTRAQ and tandem mass spectrometry. *American Journal of Translational Research* 9(9):3918–3934.

Lie PP, Cheng CY, Mruk DD. 2010. Crosstalk between desmoglein-2/desmocollin-2/Src kinase and coxsackie and adenovirus receptor/ZO-1 protein complexes, regulates blood-testis barrier dynamics. *International Journal of Biochemistry and Cell Biology* 42:975–986 DOI 10.1016/j.biocel.2010.02.010.

Lowndes M, Rakshit S, Shafraz O, Borghi N, Harmon RM, Green KJ, Sivasankar S, Nelson WJ. 2014. Different roles of cadherins in the assembly and structural...
integrity of the desmosome complex. *Journal of Cell Science* **127**:2339–2350 DOI 10.1242/jcs.146316.

Masuda R, Kijima H, Imamura N, Aruga N, Nakazato K, Oiwa K, Nakano T, Watanabe H, Ikoma Y, Tanaka M, Inokuchi S, Iwazaki M. 2012. Laminin-5 gamma2 chain expression is associated with tumor cell invasiveness and prognosis of lung squamous cell carcinoma. *Biomedical Research* **33**(5):309–317 DOI 10.2220/biomedres.33.309.

Nava P, Laukkoetter MG, Hopkins AM, Laur O, Gerner-Smidt K, Green KJ, Parkos CA, Nusrat A. 2007. Desmoglein-2: a novel regulator of apoptosis in the intestinal epithelium. *Molecular Biology of the Cell* **18**:4565–4578 DOI 10.1091/mbc.e07-05-0426.

Ormanns S, Altendorf-Hofmann A, Jackstadt R, Horst D, Assmann G, Zhao Y, Bruns C, Kirchner T, Knosel T. 2015. Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma. *British Journal of Cancer* **113**:1460–1466 DOI 10.1038/bjc.2015.362.

Overmiller AM, McGuinn KP, Roberts BJ, Cooper F, Brennan-Crispi DM, Deguchi T, Peltonen S, Wahl 3rd JK, Mahoney MG. 2016. c-Src/Cav1-dependent activation of the EGFR by Dsg2. *Oncotarget* **7**:37536–37555 DOI 10.18632/oncotarget.7675.

Pilichou K, Remme CA, Basso C, Campian ME, Rizzo S, Barnett P, Scicluna BP, Bauce B, Van den Hoff MJ, De Bakker JM, Tan HL, Valente M, Nava A, Wilde AA, Moorman AF, Thieme G, Bezzina CR. 2009. Myocyte necrosis underlies progressive myocardial dystrophy in mouse dsg2-related arrhythmogenic right ventricular cardiomyopathy. *Journal of Experimental Medicine* **206**:1787–1802 DOI 10.1084/jem.20090641.

Ponten F, Jirstrom K, Uhlen M. 2008. The human protein atlas—a tool for pathology. *Journal of Pathology* **216**:387–393 DOI 10.1002/path.2440.

Ramani VC, Hennings L, Haun RS. 2008. Desmoglein 2 is a substrate of kallikrein 7 in pancreatic cancer. *BMC Cancer* **8**:373 DOI 10.1186/1471-2407-8-373.

Saaber F, Chen Y, Cui T, Yang L, Mireskandari M, Petersen I. 2015. Expression of desmogleins 1-3 and their clinical impacts on human lung cancer. *Pathology, Research and Practice* **211**:208–213 DOI 10.1016/j.prp.2014.10.008.

Schafer S, Stumpp S, Franke WW. 1996. Immunological identification and characterization of the desmosomal cadherin Dsg2 in coupled and uncoupled epithelial cells and in human tissues. *Differentiation* **60**:99–108 DOI 10.1046/j.1432-0436.1996.6020099.x.

Siegel RL, Miller KD, Jemal A. 2018. Cancer statistics, 2018. *CA: A Cancer Journal for Clinicians* **68**:7–30 DOI 10.3322/caac.21442.

Tan LY, Mintoff C, Johan MZ, Ebert BW, Fedele C, Zhang YF, Szeto P, Sheppard KE, McArthur GA, Foster-Smith E, Ruszkiewicz A, Brown MP, Bonder CS, Shackleton M, Ebert LM. 2016. Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome. *Oncotarget* **7**:46492–46508 DOI 10.18632/oncotarget.10216.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. 2017. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Research* **45**:W98–W102 DOI 10.1093/nar/gkx247.
Trojan L, Schaaf A, Steidler A, Haak M, Thalmann G, Knoll T, Gretz N, Alken P, Michel MS. 2005. Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines. *Anticancer Research* **25**:183–191.

Ungewiss H, Rotzer V, Meir M, Fey C, Diefenbacher M, Schlegel N, Waschke J. 2018. Dsg2 via Src-mediated transactivation shapes EGFR signaling towards cell adhesion. *Cellular and Molecular Life Science* **75**:4251–4268 DOI 10.1007/s00018-018-2869-x.

Vite A, Gandjbakhch E, Prost C, Fressart V, Fouret P, Neyroud N, Gary F, Donal E, Varnous S, Fontaine G, Fornes P, Hidden-Lucet F, Komajda M, Charron P, Villard E. 2013. Desmosomal cadherins are decreased in explanted arrhythmogenic right ventricular dysplasia/cardiomyopathy patient hearts. *PLOS ONE* **8**:e75082 DOI 10.1371/journal.pone.0075082.

Wang A, Dai H, Gong Y, Zhang C, Shu J, Luo Y, Jiang Y, Liu W, Bie P. 2019. ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis. *Journal of Experimental & Clinical Cancer Research* **38**:347 DOI 10.1186/s13046-019-1340-7.

Wang HK, Liang JF, Zheng HX, Xiao H. 2018. Expression and prognostic significance of ECT2 in invasive breast cancer. *Journal of Clinical Pathology* **71**:442–445 DOI 10.1136/jclinpath-2017-204569.

Wang Y, Chen C, Wang X, Jin F, Liu Y, Liu H, Li T, Fu J. 2016. Lower DSC1 expression is related to the poor differentiation and prognosis of head and neck squamous cell carcinoma (HNSCC). *Journal of Cancer Research and Clinical Oncology* **142**:2461–2468 DOI 10.1007/s00432-016-2233-1.

Yang X, Wang J, Li WP, Jin ZJ, Liu XJ. 2015. Desmocollin 3 mediates follicle stimulating hormone-induced ovarian epithelial cancer cell proliferation by activating the EGFR/Akt signaling pathway. *International Journal of Clinical and Experimental Pathology* **8**:6716–6723.

Zhang B, Xie Z, Li B. 2019. The clinicopathologic impacts and prognostic significance of GLUT1 expression in patients with lung cancer: a meta-analysis. *Gene* **689**:76–83 DOI 10.1016/j.gene.2018.12.006.

Zhang X, Li W, Hou Y, Niu Z, Zhong Y, Zhang Y, Yang S. 2014. Comparative membrane proteomic analysis between lung adenocarcinoma and normal tissue by iTRAQ labeling mass spectrometry. *American Journal of Translational Research* **6**:267–280.